Following a transformative year in 2025, marked by validation of its PROBODY masking platform, CytomX Therapeutics Inc. (CTMX) is positioning its two clinical-stage programs for key upcoming data readouts.
The company's PROBODY therapeutic platform is designed to enable a more targeted approach to cancer treatment. PROBODY therapeutics are engineered to bind preferentially to tumor tissue while limiting activity in healthy tissue. This selectivity is achieved through a proprietary masking mechanism that temporarily blocks the therapy's target-binding region, thereby reducing activity in normal tissues.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com